Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperform rating and announces Price Target of $10.